TAS‐115 inhibits PDGFRα/AXL/FLT‐3 signaling and suppresses lung metastasis of osteosarcoma

Osteosarcoma is the most common malignant bone tumor in adolescence and childhood. Metastatic osteosarcoma has a poor prognosis with an overall 5‐year survival rate of approximately 20%. TAS‐115 is a novel multiple receptor tyrosine kinase inhibitor that is currently undergoing clinical trials. Usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuda, Naohiro, Takenaka, Satoshi, Nakai, Sho, Nakai, Takaaki, Yamada, Shutaro, Imura, Yoshinori, Outani, Hidetatsu, Hamada, Kenichiro, Yoshikawa, Hideki, Naka, Norifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193166/
https://www.ncbi.nlm.nih.gov/pubmed/32128992
http://dx.doi.org/10.1002/2211-5463.12827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193166/
https://www.ncbi.nlm.nih.gov/pubmed/32128992
http://dx.doi.org/10.1002/2211-5463.12827

Ejemplares similares